Friday, 17 Nov 2017

You are here

Golimumab Fails in Polyarticular Juvenile Arthritis

Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis. Excluding new biosimilar indications, there are 9 currently approved biologics for adult RA, but only 5 of these have been approved for use in polyarticular JIA (pJIA) - abatacept, tocilizumab, etanercept, infliximab, and adalimumab.

The efficacy and safety of golimumab (GOL) was assessed in 173 pJIA patients who received open-label GOL (30 mg/m2) every 4 weeks with weekly methotrexate for 16 weeks. Patients achivieving a JIA ACR30 by week 16 were randomized to blinded treatment with either continued golimumab or placebo. The primary outcome was JIA flares rates after week 16. 

By week 16, the JIA ACR30/50/70/90 responses were 89%, 79.2%, 65.9% and 36.4% respectively.

However after blinded randomization, a flare difference (the primary endpoint) did not distinguish between treatment groups by week 48.  The JIA flare rates between golimumab and placebo was 41% (GOL) and 47% (PBO). and clinical remissions were also comparable (12.8% vs 11.8%, respectively.

No significant differences in adverse events or serious adverse event rates were seen between groups.

Although under blinded conditions, GOL and placebo responses were similar.  These disappointing results are contrasted by high level (66% JIA ACR70) responses with open-label golimumab in active polyJIA.

There were several potential problems with trial design, including the long-half life of GOL that may hinders its performance in a double-blind withdrawal style trial.  Moreover the trial homogeneity was hampered by inclusion of a wide range of ages (ages 2–17 years) and all types of JIA RF positive or negative polyarticular, extended oligoarticular JIA, systemic JIA, juvenile psoriatic arthritis). Many of these patients did not have elevated ESR or C-reactive protein values at entry and nearly 10% of patients had previously been treated with a TNF inhibitor.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).

Adalimumab Biosimilars Adding Up

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.